AAIC – speculative Alzheimer’s groups fail to catch the Aduhelm wave
Alector, Cassava and Annovis play up mixed data in dementia, but the markets aren’t buying it.
Annovis rises on Alzheimer’s froth
The data so far do not appear to justify quite this much excitement.
2020 wins top of the froths for biotech stocks
It's official: dramatic share price jumps in response to clinical data have become more common.